V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215541 | 20081633 | 1.6 | 53.1 | Curative (C) | 2016-11-21 | 2016-11-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101168142 |
| 20215542 | 20081634 | 1.76 | 64.9 | 03 | 2017-06-28 | 2017-07-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100610274 |
| 20215543 | 20081635 | 1.69 | 63.2 | Palliative (P) | 2019-06-02 | 2019-06-02 | Trial Unspecified | Y | N | TRIAL | 100238718 |
| 20215544 | 20081636 | 1.69 | 107.2 | Curative (C) | 2019-01-22 | 2019-01-28 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100339859 |
| 20215545 | 20081637 | 1.76 | 84.6 | Palliative (P) | 2017-11-30 | 2017-12-20 | Trial Unspecified | Y | N | TRIAL | 101283128 |
| 20215546 | 20081638 | 1.64 | 60.4 | Curative (C) | 2019-11-09 | 2019-12-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100552892 |
| 20215547 | 20081639 | 0 | null | null | null | 2020-05-29 | LANREOTIDE | 02 | null | LANREOTIDE | 101857744 |
| 20215548 | 20081640 | null | 66.8 | Palliative (P) | 2017-05-30 | 2017-06-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101578864 |
| 20215549 | 20081641 | 1.49 | 86.8 | Adjuvant (A) | 2017-11-24 | 2017-12-03 | Trial Unspecified | Y | N | TRIAL | 100627660 |
| 20215550 | 20081642 | 1.62 | 81.6 | Curative (C) | 2018-09-05 | 2018-09-20 | FLUOROURACIL + MITOMYCIN + RT | null | Y | FLUOROURACIL + MITOMYCIN + RT | 100579298 |
| 20215551 | 20081643 | null | null | Curative (C) | 2016-04-27 | 2016-05-10 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101422277 |
| 20215552 | 20081644 | 1.54 | 74.5 | Curative (C) | 2016-11-01 | 2016-11-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 100215382 |
| 20215553 | 20081645 | 1.67 | 84.8 | Palliative (P) | 2017-09-24 | 2017-09-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100430302 |
| 20215554 | 20081646 | 1.64 | 51.5 | Neo-adjuvant (N) | 2016-06-09 | 2016-06-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100541872 |
| 20215555 | 20081647 | 1.68 | 73.6 | Palliative (P) | 2018-07-26 | 2018-07-29 | IMATINIB | 02 | N | IMATINIB | 100466265 |
| 20215556 | 20081648 | 1.65 | 95 | Curative (C) | 2019-08-02 | 2019-08-02 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101065036 |
| 20215557 | 20081649 | 1.66 | 83.2 | Palliative (P) | 2017-11-30 | 2017-11-30 | GO2 TRIAL | 02 | N | TRIAL | 101694850 |
| 20215558 | 20081650 | 1.6 | 83.1 | Palliative (P) | 2019-01-07 | 2019-03-26 | GO2 TRIAL | Y | N | TRIAL | 100216702 |
| 20215559 | 20081651 | null | 0 | Palliative (P) | null | 2018-05-31 | LANREOTIDE | null | N | LANREOTIDE | 101042856 |
| 20215560 | 20081652 | null | 81.4 | null | 2017-11-29 | 2017-12-10 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100034229 |
| 20215563 | 20081653 | 1.74 | 63.2 | null | 2018-05-05 | 2018-06-09 | Trial Unspecified | Y | Y | TRIAL | 101600238 |
| 20215565 | 20081654 | 1.64 | 65.3 | Palliative (P) | 2017-01-24 | 2017-02-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100419319 |
| 20215566 | 20081655 | 1.74 | 69.9 | Palliative (P) | 2018-05-21 | 2018-06-05 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100445859 |
| 20215568 | 20081656 | 1.8 | 55.8 | Palliative (P) | 2018-06-26 | 2018-06-26 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101835046 |
| 20215569 | 20081657 | 1.87 | 43.45 | Palliative (P) | 2017-04-25 | 2017-05-10 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101324448 |
| 20215570 | 20081658 | 1.75 | 78.45 | Palliative (P) | 2018-12-12 | 2018-12-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100498300 |
| 20215572 | 20081659 | 0 | 58 | Palliative (P) | 2018-05-03 | 2018-05-04 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100130273 |
| 20215573 | 20081660 | 1.65 | 82 | Palliative (P) | 2018-04-05 | 2018-04-05 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 100865769 |
| 20215574 | 20081661 | 1.66 | 79.3 | Palliative (P) | 2016-02-15 | 2016-02-26 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101681001 |
| 20215575 | 20081662 | 1.66 | 57.14 | 03 | 2016-12-04 | 2016-12-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101418065 |
| 20215576 | 20081663 | 1.72 | 60 | Curative (C) | 2018-09-12 | 2018-10-01 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100647058 |
| 20215577 | 20081664 | 1.61 | 100 | Palliative (P) | 2018-12-24 | 2019-01-02 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101361849 |
| 20215578 | 20081665 | 1.8 | 54 | Curative (C) | 2019-06-13 | 2019-06-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101144353 |
| 20215579 | 20081666 | 1.77 | 51.9 | Palliative (P) | null | 2016-11-24 | Trial Unspecified | 01 | N | TRIAL | 100649407 |
| 20215581 | 20081667 | 1.72 | 65 | Palliative (P) | 2018-10-23 | 2018-11-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101369155 |
| 20215583 | 20081669 | 1.63 | 55.4 | Palliative (P) | 2019-02-12 | 2019-03-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101562750 |
| 20215585 | 20081670 | 1.57 | 56.2 | null | 2018-03-27 | 2018-04-02 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 100805407 |
| 20215586 | 20081671 | 1.58 | 52.7 | Curative (C) | 2019-02-25 | 2019-03-24 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 100755239 |
| 20215589 | 20081673 | 1.89 | 95 | Palliative (P) | null | 2016-10-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100252894 |
| 20215590 | 20081674 | 1.8 | 76.3 | Palliative (P) | 2017-01-02 | 2017-01-21 | Trial Unspecified | Y | N | TRIAL | 100793162 |
| 20215591 | 20081675 | 1.66 | 82 | Curative (C) | 2018-06-18 | 2018-07-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101724015 |
| 20215592 | 20081676 | 1.67 | 64 | Palliative (P) | 2018-05-11 | 2018-05-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100913013 |
| 20215594 | 20081677 | 1.63 | 83.9 | Curative (C) | 2017-09-02 | 2017-09-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101626679 |
| 20215595 | 20081678 | 1.61 | 60 | Palliative (P) | null | 2019-12-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100853330 |
| 20215597 | 20081680 | 1.79 | 0 | Palliative (P) | 2016-10-07 | 2016-10-14 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101181409 |
| 20215598 | 20081681 | 0 | 79.6 | Palliative (P) | 2017-09-25 | 2017-10-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100725668 |
| 20215600 | 20081682 | 1.7 | 37.6 | null | 2018-07-11 | 2018-07-12 | Imatinib 400mg | 02 | null | IMATINIB | 101827539 |
| 20215601 | 20081683 | 0 | 97 | 03 | 2018-05-09 | 2018-05-09 | Imatinib 400mg | 02 | N | IMATINIB | 101811255 |
| 20215602 | 20081684 | 1.63 | 63 | Curative (C) | 2017-10-04 | 2017-10-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101822779 |
| 20215603 | 20081685 | 1.64 | 80.7 | Palliative (P) | 2017-11-16 | 2017-11-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101105477 |